Cochrane · systematic review · CD012785
Prostacyclin for pulmonary arterial hypertension
Barnes, H, Yeoh, HL, Fothergill, T, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
19
current version
GRADE rated
19
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 21.1%Moderate 13 · 68.4%High 2 · 10.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Prostacyclin compared to control for pulmonary arterial hypertension
Population: pulmonary arterial hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in WHO functional class Prostacyclin vs control | OR 2.39 [1.72, 3.32] | 8 studies · 1066 participants | Moderate Downgraded: risk of bias |
6MWD Prostacyclin vs control | no estimate extracted | 13 studies · 2283 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mortality Prostacyclin vs control | OR 0.6 [0.38, 0.94] | 15 studies · 2554 participants | Moderate Downgraded: risk of bias |
mPAP (the higher the mPAP, the worse the pulmonary hypertension) Prostacyclin vs control | no estimate extracted | 8 studies · 1132 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
PVR (the higher the PVR, the worse the pulmonary hypertension) Prostacyclin vs control | no estimate extracted | 7 studies · 658 participants | Moderate Downgraded: risk of bias |
Cardiac index (the lower the cardiac index, the worse the pulmonary hypertension) Prostacyclin vs control | no estimate extracted | 6 studies · 868 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
RAP (the lower the RAP, the worse the pulmonary hypertension) Prostacyclin vs control | no estimate extracted | 6 studies · 1060 participants | Moderate Downgraded: risk of bias |
Dyspnoea (lower scores indicates more severe breathlessness) Prostacyclin vs control | no estimate extracted | 8 studies · 1521 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life Prostacyclin vs control | no estimate extracted | 3 studies · 271 participants | Moderate Downgraded: risk of bias |
Headache+ Prostacyclin vs control | no estimate extracted | 12 studies · 2351 participants | Moderate Downgraded: imprecision, inconsistency |
Selexipag compared to placebo for pulmonary arterial hypertension
Population: pulmonary arterial hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in WHO functional class Selexipag vs placebo | OR 1.61 [0.17, 15.63] | 1 study · 43 participants | Moderate Downgraded: imprecision |
6MWD Selexipag vs placebo | no estimate extracted | 2 studies · 1199 participants | High |
Mortality Selexipag vs placebo | no estimate extracted | 2 studies · 1199 participants | Moderate Downgraded: imprecision |
mPAP the higher the mPAP, the worse the pulmonary hypertension) Selexipag vs placebo | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
PVR (the higher the PVR, the worse the pulmonary hypertension) Selexipag vs placebo | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
Cardiac index (the lower the cardiac index, the worse the pulmonary hypertension) Selexipag vs placebo | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
RAP (the lower the RAP, the worse the pulmonary hypertension) Selexipag vs placebo | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
Dyspnoea (lower scores indicates more severe breathlessness) Selexipag vs placebo | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
Headache+ Selexipag vs placebo | no estimate extracted | 2 studies · 1199 participants | High |